Archive for the ‘ViaCyte Inc’ Category

ViaCyte Inc

September 5th, 2014 | Posted in 2014, ViaCyte Inc

ViaCyte Inc., San Diego, has completed a private equity financing transaction providing $5.4 Million. The privately held regenerative medicine company is developing a diabetes treatment.

ViaCyte

July 30th, 2014 | Posted in 2014, ViaCyte Inc

San Diego-based Viacyte announced it has applied to begin clinical trials of its diabetes treatment. The company grows replacement insulin-producing cells from embryonic stem cells.

ViaCyte, Inc.

July 18th, 2014 | Posted in 2014, ViaCyte Inc

ViaCyte, Inc, San Diego, received an International Standards Organization (ISO) certification. The privately-held company develops cell therapy for Type 1 diabetes. VC-01, the product receiving the certification, is a combination of human stem cell derived pancreatic progenitor cells encapsulated in an immune-protective device.    

ViaCyte Inc

July 11th, 2013 | Posted in 2013, ViaCyte Inc

ViaCyte Inc – San Diego:  Announced recently that it has completed a private equity financing transaction which provides $10.6-million through the sale of Series C-1 Preferred Stock, together with Warrants to buy stock. ViaCyte is a regenerative medicine company which is focused on the development of new approaches to treat major diseases through the application […]